TCR | Jotup

TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR

Retrieved on:

Thursday, January 18, 2024

Syndrome, Patient, Therapy, Transplant, MDS, TCR, Acute myeloid leukemia, ALL, Society, Cancer, Acute leukemia, Tandem, HCT, AML, Abstract (summary)

WALTHAM, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of an abstract for oral presentation at the Best Abstracts session of the upcoming Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT®) and the Center for International Blood and Marrow Transplant Research (CIBMTR®), being held from February 21-24, 2024, in San Antonio, Texas and online. The presentation will highlight initial data from the Phase 1 multi-arm clinical trial evaluating TSC-100 and TSC-101, which are designed to treat residual disease and prevent relapse following hematopoietic cell transplantation (HCT) in patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or acute lymphocytic leukemia (ALL) (NCT05473910). The following abstract was selected by the Tandem Meetings to receive a Best Abstracts Award.

Key Points:

WALTHAM, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of an abstract for oral presentation at the Best Abstracts session of the upcoming Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT®) and the Center for International Blood and Marrow Transplant Research (CIBMTR®), being held from February 21-24, 2024, in San Antonio, Texas and online.
The presentation will highlight initial data from the Phase 1 multi-arm clinical trial evaluating TSC-100 and TSC-101, which are designed to treat residual disease and prevent relapse following hematopoietic cell transplantation (HCT) in patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or acute lymphocytic leukemia (ALL) ( NCT05473910 ).
The following abstract was selected by the Tandem Meetings to receive a Best Abstracts Award.
Location: Stars at Night B2 & B3 (Ballroom Level, Henry B. González Convention Center)
A copy of the presentation materials will be added to the “ Events and Presentations ” section of the Company’s Investor Relations website at ir.tscan.com once presentations have concluded.

Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development

Retrieved on:

Wednesday, January 24, 2024

RenBiologics business will cover out-licensing/co-development of the company’s extensive library of fully human antibodies, as well as licensing of RenMice®, the company’s fully human antibody/TCR discovery platforms.

Key Points:

RenBiologics business will cover out-licensing/co-development of the company’s extensive library of fully human antibodies, as well as licensing of RenMice®, the company’s fully human antibody/TCR discovery platforms.
The RenBiologics logo features an antibody with human-centric design elements, highlighting Biocytogen's expertise in discovering fully human antibodies; the encircled design underscores the company’s dedication to becoming a global resource of fully human antibodies to expedite the development of novel antibody-based therapeutics.
Biocytogen’s fully human antibody sequences were generated by proprietary RenMice strains, each engineered to lack a certain drug target gene.
RenMice-derived fully human antibodies can be developed into novel therapies to treat numerous cancers, inflammatory and autoimmune diseases, infectious diseases, metabolic diseases, cardiovascular diseases, and neurological diseases.

Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development

Retrieved on:

Tuesday, January 23, 2024

RenBiologics business will cover out-licensing/co-development of the company’s extensive library of fully human antibodies, as well as licensing of RenMice®, the company’s fully human antibody/TCR discovery platforms.

Key Points:

RenBiologics business will cover out-licensing/co-development of the company’s extensive library of fully human antibodies, as well as licensing of RenMice®, the company’s fully human antibody/TCR discovery platforms.
The RenBiologics logo features an antibody with human-centric design elements, highlighting Biocytogen's expertise in discovering fully human antibodies; the encircled design underscores the company’s dedication to becoming a global resource of fully human antibodies to expedite the development of novel antibody-based therapeutics.
RenMice®-derived fully human antibodies can be developed into novel therapies to treat numerous cancers, inflammatory and autoimmune diseases, infectious diseases, metabolic diseases, cardiovascular diseases, and neurological diseases.
Biocytogen offers licensing and flexible partnering models for its RenMice fully human antibody/TCR discovery platforms.

CSG Government Solutions' John Walsworth Named One of The Top 50 CEOs and Leaders of 2023

Retrieved on:

Monday, January 22, 2024

CSG, Research, Government, Child protection, Medicaid, TCR, Consultant, University, Child, State government, Computer Sciences Corporation, Information technology, Organization, Unemployment benefits, Walsworth, Management

CHICAGO, Jan. 22, 2024 /PRNewswire-PRWeb/ -- CSG Government Solutions, a national leader in government program modernization, today announced that John Walsworth, CSG's Founder, Chairman, and Chief Executive Officer, has been named among The Top 50 CEOs and Leaders of 2023 by The Consulting Report (TCR).

Key Points:

CSG Government Solutions, a national leader in government program modernization, today announced that John Walsworth, CSG's Founder, Chairman, and Chief Executive Officer, has been named among The Top 50 CEOs and Leaders of 2023 by The Consulting Report.
CHICAGO, Jan. 22, 2024 /PRNewswire-PRWeb/ -- CSG Government Solutions, a national leader in government program modernization, today announced that John Walsworth, CSG's Founder, Chairman, and Chief Executive Officer, has been named among The Top 50 CEOs and Leaders of 2023 by The Consulting Report (TCR).
The Top 50 CEOs and Leaders of 2023 are individuals leading management consulting firms who distinguish themselves by their unwavering dedication to advancing their clients' objectives.
Prior to founding CSG, Walsworth worked as a consultant for Andersen Consulting and Computer Sciences Corporation.

Latest Study Confirms GLORY’s Continued Global Leadership in Teller Cash Automation Markets

Retrieved on:

Wednesday, January 10, 2024

Technology, Other Retail, Finance, Fintech, Banking, Other Technology, Professional Services, Hardware, Data Analytics, Retail, TCR, RBR, GLR, Investment, Glory, Automation, Marketing strategy, Bank

Published on 21 December 2023, the Global Branch Transformation 2024 study showed that Glory has a 52.4% percent share of the global market for Teller Cash Recyclers.

Key Points:

Published on 21 December 2023, the Global Branch Transformation 2024 study showed that Glory has a 52.4% percent share of the global market for Teller Cash Recyclers.
Since publication of the last such report by RBR, the retail financial sector has continued to witness significant change worldwide.
Teller cash automation delivers improved accuracy, enhanced security, and greater customer interaction.
The launch of the GLR series, our latest Teller Cash Recyclers in 2023, is a demonstration of our continued investment in supporting the changing needs of our banking customers.

Adimab Announces Substantial Expansion of Research Campus

Retrieved on:

Wednesday, January 10, 2024

Over the past seven years, Adimab has added more than 400 royalty bearing therapeutic programs.

Key Points:

Over the past seven years, Adimab has added more than 400 royalty bearing therapeutic programs.
To accommodate this continual growth, Adimab has increased headcount by approximately 40% over the past three years.
“We have not expanded the footprint of our main research facility since initially occupying it in 2011,” explained Eric Krauland, President and Chief Scientific Officer of Adimab.
Antibodies from Adimab have exquisite specificity and are utilized as monospecific and multispecific therapies as well as CAR-Ts, ADCs, and other proteins.

Trammell Crow Residential Expands in Greater Boston with New Luxury Community in Peabody

Retrieved on:

Wednesday, January 10, 2024

Residential Building & Real Estate, Construction & Property, REIT, Crow, Newbury Street, Northeast Division, Northshore Mall, Housing, City, Crow Holdings, TCR, Commercial property

Trammell Crow Residential (TCR), the multifamily development platform of Crow Holdings, today announced construction has commenced on its latest Alexan community, a 180-unit, luxury multifamily residence in Peabody, Massachusetts.

Key Points:

Trammell Crow Residential (TCR), the multifamily development platform of Crow Holdings, today announced construction has commenced on its latest Alexan community, a 180-unit, luxury multifamily residence in Peabody, Massachusetts.
Alexan Peabody, a four-story, luxury multifamily development, will be located at 128 Newbury Street along Route 1.
Alexan Peabody will offer both market-rate and affordable studio, one-bedroom, two-bedroom, and three-bedroom units.
With the addition of Alexan Peabody, TCR’s Northeast apartment portfolio has more than 1,600 apartment units in various stages of development.

Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation

Retrieved on:

Friday, January 5, 2024

Conference, ESMO, APC, PRAME, Treatment, Lung cancer, Immune system, IND, TCR, HBV, CMC, HLA, Melanoma, Nivolumab, Research, PIWIL1, Cancer, Standard of care, ImmTAC, Neoplasm, HIV, Ovary, PST, Webcast, Patient, Infection, Endometrium, CTA, Skin, Pharmaceutical industry

The Company is expanding its platform into autoimmune with two first in class new bispecific candidates entering the Company’s pipeline.

Key Points:

The Company is expanding its platform into autoimmune with two first in class new bispecific candidates entering the Company’s pipeline.
The Company has updated its corporate presentation to reflect these business and strategic updates.
Additionally, the Immunocore management team will discuss these updates during a live and webcast presentation at the 42nd Annual J.P. Morgan Healthcare Conference, on Wednesday January 10, 2024, at 9:00 a.m. Pacific Standard Time (PST).
The presentation and webcast will be available in the ‘Investors/Media’ section of Immunocore’s website at www.immunocore.com.

Boehringer Ingelheim licenses multiple Dark Antigens® from Enara Bio to develop off-the-shelf immunotherapies for non-small cell lung cancer (NSCLC)

Retrieved on:

Thursday, January 4, 2024

Dark, Science, Partnership, Protein, Neoplasm, Antigen, Boehringer Ingelheim, TCR, Vaccine, Lung cancer, Boehringer, Cancer, Genome, Patient, Exercise, Senior

Enara Bio today announces that Boehringer Ingelheim has exercised its option to license a number of cancer antigens discovered and validated through the ongoing collaboration using Enara Bio’s Dark Antigen discovery platform, EDAPT®.

Key Points:

Enara Bio today announces that Boehringer Ingelheim has exercised its option to license a number of cancer antigens discovered and validated through the ongoing collaboration using Enara Bio’s Dark Antigen discovery platform, EDAPT®.
Based on the licensed antigens, Boehringer intends to develop novel off-the-shelf vaccines for the treatment of patients with NSCLC.
Under the collaboration, Enara Bio’s EDAPT platform is being used to discover and validate Dark Antigens in multiple solid tumor types.
During the antigen validation work package, Enara Bio demonstrated that the licensed antigens have several attractive characteristics as targets for immunotherapies.

Boehringer Ingelheim and 3T Biosciences enter into a second partnership to develop next-generation cancer immunotherapies

Retrieved on:

Thursday, January 4, 2024

T cell, Immunotherapy, Partnership, Boehringer Ingelheim, Trichloroethylene, Research, TCR, Cancer, Patient, Potyvirus, Vaccine

INGELHEIM, Germany and SOUTH SAN FRANCISCO, Calif., Jan. 4, 2024 /PRNewswire/ -- Boehringer Ingelheim and 3T Biosciences ("3T") today announced they have entered into a new strategic collaboration and licensing agreement focused on discovering and developing next-generation life-changing cancer immunotherapies.

Key Points:

INGELHEIM, Germany and SOUTH SAN FRANCISCO, Calif., Jan. 4, 2024 /PRNewswire/ -- Boehringer Ingelheim and 3T Biosciences ("3T") today announced they have entered into a new strategic collaboration and licensing agreement focused on discovering and developing next-generation life-changing cancer immunotherapies.
Despite the significant transformation of the cancer treatment landscape by immunotherapies, sustained remission only occurs in 15-20% of all cases of cancer.
This second research partnership with 3T builds on the successful completion of the initial research partnership announced last year by the two companies.
Boehringer Ingelheim is eligible to receive royalties on future product sales by 3T Biosciences arising from the agreement.